'For
the quarter ending March 2024, consolidated net sales (including other operating income) of Torrent Pharmaceuticals has increased 10.20% to Rs 2745 crore compared to quarter ended March 2023. Operating profit margin has jumped from 29.19% to 32.17%, leading to 21.46% rise in operating profit to Rs 883.00 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 15.88% to 14.69%. Purchase of finished goods cost rose from 10.97% to 11.29%. Employee cost decreased from 18.05% to 17.41%. Other expenses fell from 25.34% to 24.97%. Other income rose 244.44% to Rs 31 crore. PBIDT rose 24.18% to Rs 914 crore. Provision for interest fell 25.23% to Rs 80 crore. Loan funds declined from Rs 5,368.00 crore as of 31 March 2023 to Rs 4,018.00 crore as of 31 March 2024. Inventories rose to Rs 2,279.00 crore as of 31 March 2024 from Rs 2,230.00 ...
Pleaselogin & subscribe to view the full report.
More Reports
-
Revenue up 11% YoY to Rs 33562.9 crore in Q2FY2025
-
(18-Nov-2024)
Bharat Forge
-
-
|
|